Login to Your Account

Biosimilars in Europe: Lower prices, improved access, says EC report

By Nuala Moran
Staff Writer

Friday, May 5, 2017

LONDON – Two new reports from the European Commission (EC) and EMA show that 10 years on from the first approval biosimilars are having a major impact on price and patient access and there is no evidence of any differences in safety and efficacy compared to reference products.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription